AI Platforms for Biotech and Pharmaceutical Consulting
For a life-sciences consulting engagement, start with a specific deliverable: a sourced shortlist of assets that fit a client’s therapeutic-area and development criteria. The team needs to explain why each asset qualifies, where the evidence is weak and what would change the recommendation.
This guide focuses on that asset-screening workflow. Maven Bio publishes it and is one of the products discussed. The comparison uses public vendor documentation; it does not report measured productivity gains or independently tested model accuracy.
Agree the screening rules with the client
Define indication, geography, development stage, mechanism, ownership requirements and the evidence cutoff. Specify the treatment setting and patient subgroup when those determine eligibility. Keep an exclusion log so the client can distinguish an asset you evaluated and rejected from one you did not find.
For a hypothetical licensing screen, “Phase 2 assets” is not enough detail. Ask whether the client means an ongoing Phase 2 study, a completed study with results, or a program ready for a registrational trial. The choice changes the shortlist.
Match tools to the evidence you need
Maven Bio describes tools for competitive landscapes, screening and source-backed research for consulting teams. Evaluate whether the workflow can preserve your screening criteria and let a reviewer trace the evidence behind a proposed inclusion.
Maven Bio consulting workflow description
Clarivate’s Cortellis Clinical Trials Intelligence documents trial search and comparisons across endpoints, eligibility criteria, reported outcomes, sites and timelines. Evaluate it for checking the trial-level evidence behind an asset screen. Confirm which trial records and source documents the team can inspect.
Cortellis Clinical Trials Intelligence product description
AlphaSense documents research, document synthesis and monitoring. Evaluate it for the company-disclosure component of the engagement, including the evidence behind management statements. Confirm licensed content and export permissions before promising a client access to underlying material.
AlphaSense platform description
Evaluate Pharma documents consensus forecasts and historical deal information. Evaluate it for the commercial assumptions and comparable-transaction portion of the brief. Keep forecast vintages and transaction definitions visible in the deliverable.
Evaluate Pharma product description
This is a selected set of relevant capabilities, not a universal procurement list. A clinical-trial database, a research assistant and a consensus dataset serve different purposes. Ask a vendor to demonstrate the specific gap in your existing workflow.
Use an asset-screening worksheet
| Field | What the reviewer should see |
| Asset and owner | Canonical name, aliases, sponsor and disclosed rights by territory |
| Fit with the brief | Explicit inclusion criterion and the evidence supporting it |
| Clinical evidence | Study identifier, population, comparator, endpoint, follow-up and result date |
| Commercial context | Relevant alternatives, forecast vintage and material assumptions |
| Unresolved diligence | Missing results, inconsistent disclosures or ownership questions |
| Recommendation | Advance, hold or exclude, with the reviewer’s rationale |
Separate collection from interpretation
Ask the agent to collect and compare source passages before drafting the recommendation. A single favorable result should not stand in for an assessment of the full evidence. Have the scientific reviewer judge whether populations, endpoints and follow-up periods support the proposed comparison.
When two sources conflict, retain both in the working file and explain which one supports the final wording. Mark a missing result as unavailable. Do not turn absence from a search result into a claim that an asset has failed or that a competitor has no program.
Measure the engagement workflow
Pilot the tool on a completed brief for which the team knows the important inclusions and exclusions. Track missed assets, unsupported statements, source accessibility and correction time. Ask the engagement lead to review the resulting recommendation without being told which tool produced it.
Before client delivery, confirm that the cited evidence is available under the firm’s licenses and that the client can understand the assumptions. Preserve the review notes so a later update can focus on changed evidence rather than reconstructing the original analysis.
Bring your screening criteria and one representative asset to a demonstration. Ask for the evidence table, an exclusion rationale and a short draft recommendation your team can challenge.